Chunlei Zheng1,2, Nathanael R Fillmore2,3,4, Jaime Ramos-Cejudo2,5, Mary Brophy2,6, Ricardo Osorio7,8, Mark E Gurney9, Wei Qiao Qiu10,11,12, Rhoda Au13,14, George Perry15, Maureen Dubreuil2,6, Shu G Chen16, Xin Qi17, Pamela B Davis18, Nhan Do2,6, Rong Xu1,19. 1. Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 2. VA Boston Cooperative Studies Program, MAVERIC, VA Boston Healthcare System, Boston, Massachusetts, USA. 3. Harvard Medical School, Boston, Massachusetts, USA. 4. Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 5. Division of Brain Aging, Department of Psychiatry, New York University School of Medicine, New York City, New York, USA. 6. Boston University School of Medicine, Boston, Massachusetts, USA. 7. Department of Psychiatry, Healthy Brain Aging and Sleep Center, NYU Langone Medical Center, New York, New York, USA. 8. Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, New York, USA. 9. Tetra Therapeutics, Grand Rapids, Michigan, USA. 10. Department of Pharmacology and Experimental Therapeutics, Boston University Medical Campus, Boston, Massachusetts, USA. 11. Alzheimer's Disease Center, Boston University Medical Campus, Boston, Massachusetts, USA. 12. Department of Psychiatry, Boston University Medical Campus, Boston, Massachusetts, USA. 13. Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, Massachusetts, USA. 14. Boston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, Massachusetts, USA. 15. College of Sciences, The University of Texas at San Antonio, San Antonio, Texas, USA. 16. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 17. Department of Physiology & Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 18. Center for Clinical Investigation, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 19. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Abstract
INTRODUCTION: Tumor necrosis factor (TNF) inhibitors are widely used to treat rheumatoid arthritis (RA) and their potential to retard Alzheimer's disease (AD) progression has been reported. However, their long-term effects on the dementia/AD risk remain unknown. METHODS: A propensity scored matched retrospective cohort study was conducted among 40,207 patients with RA within the US Veterans Affairs health-care system from 2000 to 2020. RESULTS: A total of 2510 patients with RA prescribed TNF inhibitors were 1:2 matched to control patients. TNF inhibitor use was associated with reduced dementia risk (hazard ratio [HR]: 0.64, 95% confidence interval [CI]: 0.52-0.80), which was consistent as the study period increased from 5 to 20 years after RA diagnosis. TNF inhibitor use also showed a long-term effect in reducing the risk of AD (HR: 0.57, 95% CI: 0.39-0.83) during the 20 years of follow-up. CONCLUSION: TNF inhibitor use is associated with lower long-term risk of dementia/AD among US veterans with RA.
INTRODUCTION: Tumor necrosis factor (TNF) inhibitors are widely used to treat rheumatoid arthritis (RA) and their potential to retard Alzheimer's disease (AD) progression has been reported. However, their long-term effects on the dementia/AD risk remain unknown. METHODS: A propensity scored matched retrospective cohort study was conducted among 40,207 patients with RA within the US Veterans Affairs health-care system from 2000 to 2020. RESULTS: A total of 2510 patients with RA prescribed TNF inhibitors were 1:2 matched to control patients. TNF inhibitor use was associated with reduced dementia risk (hazard ratio [HR]: 0.64, 95% confidence interval [CI]: 0.52-0.80), which was consistent as the study period increased from 5 to 20 years after RA diagnosis. TNF inhibitor use also showed a long-term effect in reducing the risk of AD (HR: 0.57, 95% CI: 0.39-0.83) during the 20 years of follow-up. CONCLUSION: TNF inhibitor use is associated with lower long-term risk of dementia/AD among US veterans with RA.
Authors: Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer Journal: Lancet Neurol Date: 2015-04 Impact factor: 44.182
Authors: Jefferson W Kinney; Shane M Bemiller; Andrew S Murtishaw; Amanda M Leisgang; Arnold M Salazar; Bruce T Lamb Journal: Alzheimers Dement (N Y) Date: 2018-09-06